×
About 1,900 results

ALLMedicine™ Fibrosarcoma Center

Research & Reviews  706 results

Effects of Liposome-Entrapped Muramyl Tripeptide Phosphatidylethanolamine (L-MTP-PE) on...
https://doi.org/10.1055/a-1847-7312
Drug Research; Tanaka M, Abe S

Jun 30th, 2022 - Antitumor activities of L-MTP-PE (Liposome entrapped myuramyl tripeptide phosphatidylethanolamine) in the combination treatment with chemo- or immune-therapeutic antitumor agents against various syngeneic tumors were tested.Against Meth A fibrosar...

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT03027388

Jun 24th, 2022 - Background: Primary gliomas are an incurable disease in spite of aggressive multimodality therapy consisting of craniotomy, irradiation, and chemotherapy. Therapeutic options for patients with recurrent glioma are limited, and there is an unmet ne...

A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a...
https://clinicaltrials.gov/ct2/show/NCT05236257

Jun 22nd, 2022 - This is an observational study in which data from the past of children and young people with a specific cancer, called NTRK gene fusion positive infantile fibrosarcoma (IFS) is studied. IFS is a rare type of childhood cancer that commonly affects ...

Update on Mesenchymal Lesions of the Lower Female Genital Tract.
https://doi.org/10.1016/j.path.2022.02.009
Surgical Pathology Clinics; Croce S, Perret R et. al.

Jun 18th, 2022 - This article provides an update of the recent developments in mesenchymal tumors of lower genital tract. We focus on the characterization of recurrent molecular events in certain genital stromal tumors, for instance angiomyofibroblastomas and supe...

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
https://clinicaltrials.gov/ct2/show/NCT03834961

Jun 13th, 2022 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR) of children with infantile fibrosarcoma (IFS) treated with neoadjuvant larotrectinib prior to local control. SECONDARY OBJECTIVES: I. To determine event-free survival (EFS), over...

see more →

Guidelines  1 results

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatri...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903261
Current Oncology (Toronto, Ont.); Perreault S, Chami R et. al.

Jan 14th, 2021 - Neurotrophic tyrosine receptor kinase gene fusions (NTRK) are oncogenic drivers present at a low frequency in most tumour types (<5%), and at a higher frequency (>80%) in a small number of rare tumours (e.g., infantile fibrosarcoma [IFS]) and cons...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  18 results

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT03027388

Jun 24th, 2022 - Background: Primary gliomas are an incurable disease in spite of aggressive multimodality therapy consisting of craniotomy, irradiation, and chemotherapy. Therapeutic options for patients with recurrent glioma are limited, and there is an unmet ne...

A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a...
https://clinicaltrials.gov/ct2/show/NCT05236257

Jun 22nd, 2022 - This is an observational study in which data from the past of children and young people with a specific cancer, called NTRK gene fusion positive infantile fibrosarcoma (IFS) is studied. IFS is a rare type of childhood cancer that commonly affects ...

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
https://clinicaltrials.gov/ct2/show/NCT03834961

Jun 13th, 2022 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR) of children with infantile fibrosarcoma (IFS) treated with neoadjuvant larotrectinib prior to local control. SECONDARY OBJECTIVES: I. To determine event-free survival (EFS), over...

Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
https://clinicaltrials.gov/ct2/show/NCT01434602

Jun 1st, 2022 - Background Although malignant gliomas display genetic heterogeneity, several key proliferation and survival signaling pathways have been identified. Recent work has focused on targeting these tumor specific pathways in hopes of improving treatment...

A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
https://clinicaltrials.gov/ct2/show/NCT03092323

Mar 28th, 2022 - This is a multicenter, randomized phase II trial with an initial safety run-in to test the safety and efficacy of neoadjuvant pembrolizumab with image-guided radiotherapy and adjuvant pembrolizumab compared to radiation therapy alone in patients w...

see more →

News  29 results

Clinical Management of NTRK+ Advanced NSCLC
https://www.onclive.com/view/clinical-management-of-ntrk-advanced-nsclc

Oct 12th, 2021 - Ben Levy, MD: There are now 2 TRK [tyrosine receptor kinase] inhibitors that are active, proven and FDA approved for TRK fusion-positive lung cancer. The first is larotrectinib. This was initially published in the New England Journal of Medicine l...

NTRK- and RET-Targeted Agents Reshape Solid Tumor Landscape
https://www.onclive.com/view/ntrk-and-ret-targeted-agents-reshape-solid-tumor-landscape

Aug 5th, 2021 - Understanding the oncogenic drivers behind a cancer is taking on increasing importance as more effective agents targeting specific gene aberrations continue to emerge. Two classes of precision agents that have recently had drugs come onto the mark...

Larotrectinib Elicits Robust Responses in TRK Fusion Cancer
https://www.onclive.com/view/larotrectinib-elicits-robust-responses-in-trk-fusion-cancer

Jun 5th, 2021 - The highly selective, central nervous system (CNS)-active TRK inhibitor larotrectinib (Vitrakvi) yielded promising response rates in patients with TRK fusion cancer, including in those with CNS metastases at baseline, according to the results of a...

Genomic Era Reaches Pediatric Oncology
https://www.onclive.com/view/genomic-era-reaches-pediatric-oncology

Dec 5th, 2020 - Rajen Mody, MBBS The relative rarity of pediatric cancers has hampered the work of uncovering their causes and developing new therapies, but efforts to expand the use of genomic and biomarker testing are beginning to provide new options for child...

FDA Grants Larotrectinib Priority Review for NTRK+ Cancers
https://www.onclive.com/view/fda-grants-larotrectinib-priority-review-for-ntrk-cancers

Dec 4th, 2020 - Anna F. Farago, MD, PhD The FDA has granted a priority review to a new drug application (NDA) for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK gene fusion, according...

see more →

Patient Education  4 results see all →